Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc.

Native name	久光製薬株式会社
Type	Public KK
Traded as	: : 4530 : 4530
Industry	Pharmaceuticals
Founded	(1847; 170 years ago (1847))
Headquarters	Tosu, Saga 841-0017, Japan (Kyushu head office) Marunouchi, Chiyoda, Tokyo100-6330, Japan (Tokyo head office)
Key people	Hirotaka Nakatomi (President and CEO)
Products	Salonpas and other pain relief products Robitussin, Caltrate, Advil Eye drops Anti fungal, anti-inflammatory, dermatologic, central nerve system, respiratory system medicines
Revenue	JPY 150.63 billion (FY 2013) (US$ 1.47 billion) (FY 2013)
Net income	JPY 21.35 billion (FY 2013) (US$ 209.5 million) (FY 2013)
Number of employees	2,949 (consolidated, as of February 28, 2014)
Website	Official website
Footnotes / references

JPY 150.63 billion (FY 2013)

JPY 21.35 billion (FY 2013)

Hisamitsu Pharmaceutical Co., Inc. (久光製薬株式会社, Hisamitsu Seiyaku Kabusiki-gaisha^?), headquartered in Saga and Tokyo, Japan is a pharmaceutical company that develops and markets prescription and over-the-counter drug (OTC) products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialized in transdermal drug delivery system technology (TDDS) since the introduction of its original line of patches in 1903.

Its Salonpas brand of products are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape line of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eye drops for general application and the Lifecella Face Mask, a skin-care product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration (FDA).